ストックスクリーナーアプリを入手
396.12
0.20%
-0.81
アフターアワーズ：
397.00
0.88
+0.22%
前日終値:
$396.93
開ける：
$397.87
24時間の取引高:
1.16M
Relative Volume:
0.72
時価総額：
$101.56B
収益：
$11.39B
当期純損益:
$3.64B
株価収益率:
28.31
EPS:
13.99
ネットキャッシュフロー:
$3.50B
1週間 パフォーマンス:
+1.30%
1か月 パフォーマンス:
+5.64%
6か月 パフォーマンス:
-19.43%
1年 パフォーマンス:
-15.46%
1日の値動き範囲:
$393.43
$402.74
1週間の範囲:
$390.51
$402.74
52週間の値動き範囲:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Is Vertex Pharmaceuticals Incorporated still worth holding after the dip2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Relative strength of Vertex Pharmaceuticals Incorporated in sector analysisPortfolio Return Report & Real-Time Market Sentiment Alerts - Newser
Volatility clustering patterns for Vertex Pharmaceuticals IncorporatedRate Hike & High Yield Equity Trading Tips - Newser
Vertex Pharma, Enlaza sign R&D pact worth up to $2B plus equity - MSN
Vertex Pharmaceuticals and Enlaza Therapeutics Partner in $2.4 Billion Deal to Develop Autoimmune Disease Therapies - geneonline.com
Is Vertex Pharmaceuticals Incorporated stock reversal real or fakeWeekly Earnings Recap & Long-Term Investment Growth Plans - Newser
Is Vertex Pharmaceuticals Incorporated attractive for institutional investorsMarket Weekly Review & Accurate Buy Signal Notifications - خودرو بانک
Using Bollinger Bands to evaluate Vertex Pharmaceuticals Incorporated2025 Trade Ideas & Reliable Intraday Trade Plans - Newser
Is Vertex Pharmaceuticals Incorporated meeting your algorithmic filter criteriaDip Buying & High Accuracy Swing Entry Alerts - Newser
Is Vertex Pharmaceuticals Incorporated part of any major indexJuly 2025 Selloffs & AI Powered Buy/Sell Recommendations - خودرو بانک
Is Vertex Pharmaceuticals Incorporated in a bullish channelQuarterly Performance Summary & AI Powered Market Entry Strategies - خودرو بانک
Automated trading signals detected on Vertex Pharmaceuticals IncorporatedWeekly Market Report & Reliable Price Breakout Signals - Newser
What is Vertex Pharmaceuticals Incorporated s revenue forecastEarnings Beat & Real-Time Buy Signal Alerts - خودرو بانک
Enlaza Therapeutics and Vertex Pharmaceuticals Announce $2.4 Billion Collaboration to Develop Autoimmune Disease Therapies - geneonline.com
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysisRecession Risk & Weekly Momentum Stock Picks - Newser
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzedJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Signals and Key Fundamentals to Watch - AInvest
Is Vertex Pharmaceuticals Incorporated subject to activist investor interest2025 Pullback Review & Safe Entry Momentum Stock Tips - خودرو بانک
Hedge Fund Moves: Is Vertex Pharmaceuticals Incorporated stock trending bullishJuly 2025 Closing Moves & Fast Moving Stock Watchlists - خودرو بانک
Why This Biotech Company Could Be a Growth Stock Powerhouse - Mitrade
Why This Biotech Company Could Be a Growth Stock Powerhouse - The Motley Fool
Why is Vertex Pharmaceuticals Incorporated stock going upQuarterly Growth Report & Low Volatility Stock Suggestions - خودرو بانک
Enlaza Therapeutics Forms $2.4 Billion Collaboration with Vertex Pharmaceuticals - Pharmaceutical Executive
Vertex Pharmaceuticals: Raymond James Initiates Coverage with Market Perform Rating - AInvest
Transcript : Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 11 - MarketScreener
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? - sg.finance.yahoo.com
Enlaza takes the helm in a $2B+ Vertex deal - BioWorld MedTech
Why Vertex Pharmaceuticals (VRTX) Is on Loomis Sayles Growth Fund’s Detractors List - AInvest
Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List - Insider Monkey
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途牛牛
Top chart patterns to watch in Vertex Pharmaceuticals IncorporatedWeekly Trade Report & Fast Gaining Stock Reports - Newser
Vertex teams with Enlaza to expand gene therapy options - The Pharma Letter
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Tools to assess Vertex Pharmaceuticals Incorporated’s risk profileGap Up & Weekly Market Pulse Updates - Newser
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Sentiment analysis tools applied to Vertex Pharmaceuticals Incorporated2025 Market WrapUp & Safe Entry Zone Tips - Newser
Does Vertex Pharmaceuticals Incorporated meet Warren Buffett’s criteriaQuarterly Trade Review & Growth-Oriented Investment Plans - khodrobank.com
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Vertex Stock Surges 2.55% on 44% Volume Spike to $740M Ranking 135th as $2B Collaboration with Enlaza Drives Strategic Expansion - AInvest
Vertex locks on to $2B covalent biologics deal with Enlaza - firstwordpharma.com
Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Fundamental Recap & Safe Entry Zone Tips - khodrobank.com
Enlaza Therapeutics strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers - MarketScreener
Vertex Pharmaceuticals Partners with Enlaza Therapeutics in $45 Million Deal to Develop Autoimmune and Gene-Editing Therapies - geneonline.com
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pact - Endpoints News
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact - biospace.com
Vertex Pharma and Enlaza Therapeutics Partner for Up to $2B in R&D Deal - AInvest
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings - Yahoo Finance
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases | VR - GuruFocus
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - Business Wire
Aug EndMonth: Does Vertex Pharmaceuticals Incorporated have declining or rising EPS2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - خودرو بانک
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
0.34%
大文字化:
|
ボリューム (24 時間):